Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 2522 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study
Augusta Ortolan¹, Mariagrazia Lorenzin¹, Giulia Tadiotto¹, Francesca Oliviero¹, Ariela Hoxha¹, Marta Favero², Stefano Piaserico³, Leonardo Punzi¹ and Roberta Ramonda¹, ¹Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit,Department of Medicine DIMED, University of Padova, Padova, Italy, ³Dermatology Clinic, University of Padova, Padova, Italy
Background/Purpose: Metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD, potentially evolving into liver fibrosis-LF), are more frequent in patient with psoriasis (PsO) with respect…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 36 • 2017 Pediatric Rheumatology Symposium
The Association of Obesity with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Timothy G. Brandon¹, Alexis Ogdie-Beatty³ and Pamela Weiss⁴, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Obesity is associated with a significantly increased risk of inflammatory arthritis in adult patients with psoriasis. Obese adults with psoriatic arthritis (PsA) also…
Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alan Menter², Philip J Mease³, Sunil Kalia⁴, Francisco Kerdel⁵, Shelly Kafka⁶, James Morgan⁶, Wayne Langholff⁷, Steve Fakharzadeh⁶, Kavitha Goyal⁶ and Alice Gottlieb⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Baylor Research Institute, Dallas, TX, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of Miami, Miami, FL, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Tufts University School of Medicine (affiliation at the time of the study), Boston, MA
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…
Abstract Number: 3185 • 2016 ACR/ARHP Annual Meeting
Sensitivity Analysis for the Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Uyen-Sa D.T. Nguyen^1,2, Yuqing Zhang², David T. Felson^2,3,4, Michael P. Lavalley⁵ and Hyon K. Choi⁶, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁵Biostatistics, Boston University School of Public Health, Boston, MA, ⁶Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Smoking is a strong risk factor for psoriasis and psoriatic arthritis, but several studies have found that smoking is inversely associated with the risk…
Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting
Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J Mease¹, Alice Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, Soumya Chakravarty⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷, Kavitha Goyal⁷ and Jose U. Scher^9,10, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…
Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Diamant Thaci¹, Akimichi Morita², Julie Birt³, Chen-Yen Lin³, Catherine L. Shuler³ and Alice B. Gottlieb⁴, ¹Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ²Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Tufts University School of Medicine, Boston, MA
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…
Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting
Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis
Julia Manasson¹, Soumya M. Reddy¹, Andrea L. Neimann², Leopoldo N. Segal³ and Jose U. Scher¹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Dermatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2164 • 2016 ACR/ARHP Annual Meeting
Depression and the Risk of Psoriatic Arthritis Among Patients with Psoriasis: A Population-Based Cohort Study
Ryan Lewinson^1,2, Isabelle Vallerand^1,3, Mark Lowerison³, Laurie Parsons⁴, Alexandra Frolkis^1,3, Gilaad Kaplan^3,4, Andrew Bulloch^3,5,6, Scott Patten^3,5 and Cheryl Barnabe^3,4, ¹Leaders in Medicine Program, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Biomedical Engineering Program, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Depression and the Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Cohort Study Background/Purpose: The factors that contribute to the development of psoriatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].